171 related articles for article (PubMed ID: 25756144)
1. Human papillomavirus vaccination for boys.
Quinn S; Goldman RD
Can Fam Physician; 2015 Jan; 61(1):43-6. PubMed ID: 25756144
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada.
McClure CA; MacSwain MA; Morrison H; Sanford CJ
Vaccine; 2015 Apr; 33(15):1786-90. PubMed ID: 25731789
[TBL] [Abstract][Full Text] [Related]
3. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccine: recommendations, issues and controversies.
Fisher R; Darrow DH; Tranter M; Williams JV
Curr Opin Pediatr; 2008 Aug; 20(4):441-5. PubMed ID: 18622201
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
9. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
[TBL] [Abstract][Full Text] [Related]
11. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
13. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Public Health Human Papillomavirus Immunization Programs in Canada.
Goyette A; Yen GP; Racovitan V; Bhangu P; Kothari S; Franco EL
Curr Oncol; 2021 Feb; 28(1):991-1007. PubMed ID: 33617515
[No Abstract] [Full Text] [Related]
15. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.
Graham DM; Isaranuwatchai W; Habbous S; de Oliveira C; Liu G; Siu LL; Hoch JS
Cancer; 2015 Jun; 121(11):1785-92. PubMed ID: 25867018
[TBL] [Abstract][Full Text] [Related]
16. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.
Durham DP; Ndeffo-Mbah ML; Skrip LA; Jones FK; Bauch CT; Galvani AP
Proc Natl Acad Sci U S A; 2016 May; 113(18):5107-12. PubMed ID: 27091978
[TBL] [Abstract][Full Text] [Related]
17. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
19. Age-based programs for vaccination against HPV.
Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
[TBL] [Abstract][Full Text] [Related]
20. Canadian school-based HPV vaccine programs and policy considerations.
Shapiro GK; Guichon J; Kelaher M
Vaccine; 2017 Oct; 35(42):5700-5707. PubMed ID: 28893472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]